In medicine, we have increasingly focused on caring for our patients in an ''evidence-based'' manner. We want to employ diagnostic and therapeutic strategies based on the best validated information that is available. This immediately raises a question about how ''good'' the evidence upon which we act is. There are several components to assessing if the data we employ are ''good'': the scientific validity of the studies; the validity of the analysis of the data; the ethical components of the studies, including potential biases. For medicine and therapeutics, integrity is the bedrock of all we do, and little is more important than the integrity of data and information on which clinical decisions are made. It is our expectation that our scientific data and clinical trials provide physicians and patients with valid information to support clinical decision making, to select the correct intervention, and to understand how to assess positive and negative outcomes. The ''therapeutic relationship'' between patient and physician, the ability to practice ''shared decision making,'' depends on public confidence in the scientific and medical enterprise. Every time that trust is breeched, those who lose the most are those whose very lives depend on the honesty and validity of biomedical enterprise. Recently, the Institute of Medicine published a review, The Sharing of Clinical Trial Data: Maximizing Benefits, Minimizing Risk, that affirms our need for data transparency, as well as the complexities of ensuring that all aspects of the scientific enterprise indeed engage in thoughtful application of the principles of data sharing. 1 How does this affect a journal and its publication policies? We are a bit of an atypical biomedical journal. We are certainly not a standard pharmacology journal, although we are typically characterized under this category. We do not publish the results of clinical trials per se. Rather, many of our published articles deal with the design of trials, statistical analyses of studies, methods for assessing safety in drug development and postmarketing, the regulatory science of assessing data and drug approval, and the communication of new information. Ours is a journal crossing disciplines; often publishing consensus statements of working groups across academia, industry, and the regulatory community; and often comparing and contrasting legislative and regulatory approaches across the globe. Many of our papers from the pharmaceutical and clinical trial industries derive from multiple company working groups (often including academic and regulatory colleagues) and address challenges that face all who work in the discovery and development of new medical products. Thus, our focus is more on how to develop scientifically valid data in the context of regulated studies rather than on publishing comparisons of drug X versus placebo or another drug.
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While not typically publishing comparative clinical trials or epidemiologic studies, we still must strive to ensure that all that we do as a journal is at the highest ethical standards, and work to prevent even the appearance of potential conflicts of interest. In this issue of TIRS, there is an erratum statement regarding the conflict of interest and funding statements in one of our previously published articles. 2 There was NO ethical issue in the article itself or in the way information was provided to TIRS by the authors; it was only a publishing error, but once pointed out to us, we felt an obligation to be completely transparent and to correct the error. We fully support the International Committee of Medical Journal Editors (ICMJE) approach to disclosure of potential conflicts of interest, and we have implemented use of the ICMJE disclosure form for all authors, to ensure that the conflict of interest statements in TIRS will meet ICMJE standards. The ''auto-generation'' aspect of using the form, and additional cross-checking in our editorial and publishing offices, will help prevent errors such as that which occurred in this instance. This is not a ''box-checking'' exercise, another form generating more ''paperwork'' for authors. Rather, use of the form by all authors reinforces the underpinning of integrity and transparency for us all; it will be a requirement of publication that this disclosure form be reviewed, approved, and submitted by the corresponding author for all articles. As publishers of high-quality articles on therapeutic innovation and regulatory science, we must continue to present the highest ethical standards and work to prevent even the appearance of potential conflicts of interest.
-Stephen P. Spielberg, MD, PhD Editor-in-Chief, DIA Publications
